Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rebastinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 7/20 | 1.00 |
| ▸ | BRAF | P15056 | 8/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 7/20 | 1.00 |
| ▸ | SRC | P12931 | 3/20 | 1.00 |
| ▸ | RIPK1 | Q13546 | 2/20 | 1.00 |
| ▸ | AXL | P30530 | 2/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | ACOX3 | O15254 | 1/20 | 1.00 |
| ▸ | MAP3K7 | O43318 | 1/20 | 1.00 |
| ▸ | DYRK3 | O43781 | 1/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 1.00 |
| ▸ | ERN1 | O75460 | 1/20 | 1.00 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | RAF1 | P04049 | 1/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | CDK1 | P06493 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rebastinib SCHEMBL29733447 | 1.00 | BRAF (1.00) | BRAFABL1MAPK14SRCRIPK1 | |
| Rebastinib SCHEMBL2034290 | 1.00 | BRAF (1.00) | BRAFABL1MAPK14SRCRIPK1 | |
| Rebastinib SCHEMBL30499050 | 1.00 | BRAF (1.00) | BRAFABL1MAPK14SRCRIPK1 | |
| Rebastinib SCHEMBL2026623 | 0.99 | BRAF (0.99) | BRAFABL1MAPK14SRCRIPK1 | |
| Rebastinib SCHEMBL29733460 | 0.99 | BRAF (0.99) | BRAFABL1MAPK14SRCRIPK1 | |
| Rebastinib SCHEMBL12079461 | 0.95 | BRAF (0.91) | BRAFABL1MAPK14SRCRIPK1 | |
| SCHEMBL2024402 | 0.94 | BRAF (0.89) | BRAFABL1MAPK14SRCRIPK1 | |
| SCHEMBL20033385 | 0.94 | MAPK14 (0.89) | BRAFABL1MAPK14SRCRIPK1 | |
| SCHEMBL18814248 | 0.94 | MAPK14 (0.88) | BRAFABL1MAPK14SRCRIPK1 | |
| Rebastinib SCHEMBL16704166 | 0.94 | BRAF (0.88) | BRAFABL1MAPK14SRCRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1485 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2026-04-07 | — | — | US | claimed |
| EP-4680251-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | Thomas Jefferson University (US) | 2026-01-21 | — | — | EP | claimed |
| US-12522873-B2 | ALK and NTRK1 fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2026-01-13 | — | — | US | claimed |
| EP-4642484-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| EP-4642492-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| WO-2025216949-A1 | METHODS FOR TREATING A TUMOR WITH ANTI-CDH6 ANTIBODY DRUG CONJUGATES | ONCUSP THERAPEUTICS, INC. (US) | 2025-10-16 | — | — | WO | claimed |
| US-20250312349-A1 | COMPOSITION AND METHODS OF TREATING INTRACELLULAR PATHOGEN INFECTION | UNIV HOSPITALS CLEVELAND MEDICAL CENTER (US) | 2025-10-09 | — | — | US | claimed |
| US-12419891-B2 | Compositions for the treatment of pathogenic- and/or chemical-induced lung injury and for the treatment of cancer and methods of using same | DUKE UNIVERSITY (US) | 2025-09-23 | — | — | US | claimed |
| EP-4604920-A1 | LYOPHILIZED FORMULATIONS OF CD73 COMPOUNDS | Arcus Biosciences, Inc. (US) | 2025-08-27 | — | — | EP | claimed |
| US-20250228851-A1 | ALLOSTERIC INHIBITOR COMPOUNDS FOR OVERCOMING CANCER RESISTANCE | NAJAJREH YOUSEF (JO) | 2025-07-17 | — | — | US | claimed |
| WO-2022225972-A1 | COMPOUNDS WITH IMPROVED CARDIAC SAFETY FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2022-10-27 | — | — | WO | claimed |
| EP-4077690-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | Engine Biosciences Pte. Ltd. (SG) | 2022-10-26 | — | — | EP | claimed |
| EP-4073516-A1 | METHODS OF TREATING CANCER PATIENTS WITH RAS NODE OR RTK TARGETED THERAPEUTIC AGENTS | Celcuity Inc. (US) | 2022-10-19 | — | — | EP | claimed |
| EP-4036583-A1 | TARGETING KINASES FOR THE TREATMENT OF CANCER METASTASIS | Board of Regents, The University of Texas System (US) | 2022-08-03 | — | — | EP | claimed |
| CN-114585356-A | Methods of preventing or treating diseases associated with VEGFR and/or VEGF inhibition | 上海岸阔医药科技有限公司 | 2022-06-03 | — | — | CN | claimed |
| WO-2022078524-A2 | SPECIFIC CONJUGATION OF AN ANTIBODY | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2022-04-21 | — | — | WO | claimed |
| US-20220096818-A1 | Compositions And Methods For Increasing Cancer Cell Sensitivity To Alternating Electric Fields | BIOPHARMA CREDIT PLC (GB) | 2022-03-31 | — | — | US | claimed |
| CN-114028568-A | Method for preventing or treating side effects of tumor therapy | 上海岸阔医药科技有限公司 | 2022-02-11 | — | — | CN | claimed |
| WO-2022029628-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2022-02-10 | — | — | WO | claimed |
| CN-113975264-A | Method for preventing or treating side effects of tumor therapy | 上海岸阔医药科技有限公司 | 2022-01-28 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250228851-A1 | ALLOSTERIC INHIBITOR COMPOUNDS FOR OVERCOMING CANCER RESISTANCE | ABCC1, KRAS, ING2 | ABL1 33/4885BRAF 806/4885MAPK14 897/4885 |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | PTK2, GSK3B, MTOR | ABL1 751/4885BRAF 26/4885MAPK14 560/4885 |
| US-12419891-B2 | Compositions for the treatment of pathogenic- and/or chemical-induced lung injury and for the treatment of cancer and methods of using same | DDIT3, MCL1, MYD88 | ABL1 938/4885BRAF 541/4885MAPK14 1705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.